| Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA |
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting May 30 – June 3 and the 2025 European Hematology Association (EHA) Annual Congress June 12 – 15. The studies span breast cancer and other solid tumors (glioblastoma, endometrial cancer, lung cancer, gastric cancer), as well as multiple blood cancers (multi. |
businesswire.com |
2025-05-15 20:15:00 |
Czytaj oryginał (ang.) |
| Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? |
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-05-15 14:01:04 |
Czytaj oryginał (ang.) |
| Gilead Sciences, Inc. (GILD) BofA Securities Health Care Conference Transcript |
Gilead Sciences, Inc. (NASDAQ:GILD ) BofA Securities Health Care Conference May 13, 2025 2:20 PM ET Company Participants Johanna Mercier – Chief Commercial Officer Conference Call Participants Tim Anderson – Bank of America Tim Anderson Thanks for joining us. I'm Tim Anderson, the U.S. large cap pharma and biotech analyst of Bank of America and excited to have Gilead with us today, specifically Johanna Mercier, who serves as the company's Chief Commercialization Officer overseeing the global commercialization of the company's medicines across really all areas. |
seekingalpha.com |
2025-05-13 23:32:37 |
Czytaj oryginał (ang.) |
| Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices |
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices. |
youtube.com |
2025-05-12 16:36:24 |
Czytaj oryginał (ang.) |
| Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet |
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach. |
seekingalpha.com |
2025-05-12 16:30:03 |
Czytaj oryginał (ang.) |
| 2 High-Yield Dividend Stocks to Buy in May and Hold Forever |
When investing in dividend stocks, paying attention to the right things is essential. A high yield can be attractive, but the most critical factor to consider is a company's underlying operations. |
fool.com |
2025-05-10 12:45:00 |
Czytaj oryginał (ang.) |
| Pressure is still on the pharma sector, says Mizuho's Jared Holz |
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector. |
youtube.com |
2025-05-08 23:23:04 |
Czytaj oryginał (ang.) |
| Gilead announces $11 billion in new investments in US |
Gilead Sciences on Wednesday announced $11 billion in capital and operational investments in the U.S. to supplement an already planned spending of $21 billion in domestic manufacturing and R&D through 2030. |
reuters.com |
2025-05-07 18:52:48 |
Czytaj oryginał (ang.) |
| Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable HDV RNA at end of treatment (EOT). In participants who sustained u. |
businesswire.com |
2025-05-07 06:30:00 |
Czytaj oryginał (ang.) |
| Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical response in adults with PBC regardless of prior treatment history. Another analysis provides evidence supporting that Livdelzi delivered clinically and. |
businesswire.com |
2025-05-07 06:15:00 |
Czytaj oryginał (ang.) |
| Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-05 14:46:30 |
Czytaj oryginał (ang.) |
| 3 Biotech Giants Gaining From U.S. Sales and Policy Shifts |
In today's unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those that don't rely too heavily on international markets. |
marketbeat.com |
2025-05-02 11:02:25 |
Czytaj oryginał (ang.) |
| Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss? |
GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure. |
zacks.com |
2025-04-30 14:10:48 |
Czytaj oryginał (ang.) |
| Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? |
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2025-04-30 14:06:02 |
Czytaj oryginał (ang.) |
| Gilead Sciences to Present at Upcoming Investor Conferences |
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 13 at 11:20 AM Pacific Time RBC Capital Markets Global Healthcare Conference on Wednesday, May 21 at 11:30 AM Eastern Time Bernstein Annual Strategic Decisions Conference on Thursday, May 29 at 2:30 PM Eastern Time Jefferies Global Healthcare Conference on Wednesday, June 4 at. |
businesswire.com |
2025-04-29 20:05:00 |
Czytaj oryginał (ang.) |
| Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors |
Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying kickbacks to doctors who agreed to prescribe its HIV drugs, the U.S. attorney's office in Manhattan said on Tuesday. |
reuters.com |
2025-04-29 17:51:22 |
Czytaj oryginał (ang.) |
| Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions |
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions |
cnbc.com |
2025-04-29 17:45:07 |
Czytaj oryginał (ang.) |
| Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, May 7-10, 2025, Amsterdam, furthering Gilead's commitment to transform the lives of people living with liver disease. New data to be presented at EASL will include a subgroup analysis from ASSURE, an ongoing open-label study, and an analysis of the Phase 3 RESPONSE trial and the open-label extension. Data w. |
businesswire.com |
2025-04-29 12:30:00 |
Czytaj oryginał (ang.) |
| Why Gilead Sciences Stock Slipped Today |
Gilead Sciences (GILD -2.85%) didn't have a bad first quarter, but investors didn't find it inspiring either. After publishing its earnings report after market close Thursday, the company saw its share price decline in excess of 2% the following day. |
fool.com |
2025-04-25 20:43:36 |
Czytaj oryginał (ang.) |
| GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline |
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down. |
zacks.com |
2025-04-25 15:45:48 |
Czytaj oryginał (ang.) |
| Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know |
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2025-02-27 12:05:53 |
Czytaj oryginał (ang.) |
| Why Gilead Sciences Remains A Buy After A 40% Rally |
Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was driven by rising demand for Biktarvy, Descovy, and Sunlenca. So, sales of Biktarvy, the flagship of Gilead's HIV franchise, amounted to $3.77 billion, an increase of 21.4% year-on-year. |
seekingalpha.com |
2025-02-27 00:55:21 |
Czytaj oryginał (ang.) |
| 4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty |
Here are four PEG-based GARP picks, GILD, EXEL, SYF and TAP, which qualify our screening criteria. |
zacks.com |
2025-02-25 14:10:48 |
Czytaj oryginał (ang.) |
| European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company's Marketing Authorization Application (MAA) and EU-Medicines for all (EU-M4all) application for lenacapavir—the company's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). Based on the assessment of EMA's Committee for Medicinal Products for Human Us. |
businesswire.com |
2025-02-24 10:30:00 |
Czytaj oryginał (ang.) |
| Gilead Sciences: 4 Reasons This Stock Has Much More To Rise |
Gilead Sciences Inc. NASDAQ: GILD stock surged to a new 52-week high at $106.69 recently on its fourth quarter of 2024 earnings release. After being asleep for so many years, the stock has finally found interest again, hitting price levels not seen in a decade. |
marketbeat.com |
2025-02-22 09:16:15 |
Czytaj oryginał (ang.) |
| Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Seladelpar (an orphan designated product) is now approved and will provide an important treatment o. |
businesswire.com |
2025-02-20 18:30:00 |
Czytaj oryginał (ang.) |
| GILD or VRTX: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-02-20 14:45:38 |
Czytaj oryginał (ang.) |
| Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year? |
Here is how Gilead Sciences (GILD) and Natera (NTRA) have performed compared to their sector so far this year. |
zacks.com |
2025-02-20 12:40:49 |
Czytaj oryginał (ang.) |
| Gilead Sciences to Present at Upcoming Investor Conferences |
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday, March 4 at 11:10 AM Eastern Time Leerink Partners Global Healthcare Conference on Tuesday, March 11 at 10:40 AM Eastern Time The live webcasts can be accessed at the company's investors page at investors.gilead.com. The replays will be available for at least 30 days following the. |
businesswire.com |
2025-02-19 18:05:00 |
Czytaj oryginał (ang.) |
| Calls of the Day: Gilead Sciences and Merck |
The Investment Committee debate the Calls of the Day in two biotech names. |
youtube.com |
2025-02-18 14:59:40 |
Czytaj oryginał (ang.) |
| U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA will review the applications under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 19, 2025. Acceptance. |
businesswire.com |
2025-02-18 10:30:00 |
Czytaj oryginał (ang.) |
| Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell? |
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. |
zacks.com |
2025-02-17 16:41:12 |
Czytaj oryginał (ang.) |
| Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue? |
Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2025-02-17 12:16:10 |
Czytaj oryginał (ang.) |
| Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy? |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-02-13 12:56:28 |
Czytaj oryginał (ang.) |
| Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention |
Tuesday, Gilead Sciences Inc GILD reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70. |
benzinga.com |
2025-02-12 17:22:27 |
Czytaj oryginał (ang.) |
| Why Gilead Sciences Stock Is Jumping Today |
Shares of Gilead Sciences (GILD 7.14%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year financial results following market close on Tuesday. |
fool.com |
2025-02-12 14:21:07 |
Czytaj oryginał (ang.) |
| Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy? |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-12 12:46:39 |
Czytaj oryginał (ang.) |
| GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance |
Gilead Sciences' Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is trading up. |
zacks.com |
2025-02-12 11:31:10 |
Czytaj oryginał (ang.) |
| Pharma Stock Surges on Beat-and-Raise |
Shares of Gilead Sciences Inc (NASDAQ:GILD) are up 4% in premarket trading, after the company delivered a strong fourth-quarter earnings beat. |
schaeffersresearch.com |
2025-02-12 11:06:26 |
Czytaj oryginał (ang.) |
| Gilead Sciences: Strong Q4 Results And Huge Progress In HIV |
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% effectiveness in Phase 3 trials, gained FDA approval and is a major breakthrough in HIV prevention. Gilead's diversified growth includes significant gains in oncology and liver disease, with Trodelvy and Livdelzi showing strong sales and robust potential for growth. |
seekingalpha.com |
2025-02-12 10:25:29 |
Czytaj oryginał (ang.) |
| Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors |
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $91.41, denoting a -0.51% change from the preceding trading day. |
zacks.com |
2025-01-03 21:11:44 |
Czytaj oryginał (ang.) |
| Jefferies Top 2025 Stock Picks Include 5 Sizzling Large Cap Dividend Blue Chips |
As the calendar turns over to 2025, the leading Wall Street firms are releasing their top stock picks for the new year. |
247wallst.com |
2025-01-03 18:05:31 |
Czytaj oryginał (ang.) |
| Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise |
Gilead's stock is rated a "buy" due to its thriving HIV business, promising oncology pipeline, and potential for long-term growth despite some volatility. The company's Q3 earnings show strong performance in HIV treatments, with Biktarvy leading and new regimens expected by 2030, and upgraded 2024 guidance for >$28bn revenues, EPS of >$4. Liver disease and oncology divisions have slightly underperformed but show potential for growth, especially with new acquisitions and upcoming drug approvals. |
seekingalpha.com |
2024-12-29 05:51:17 |
Czytaj oryginał (ang.) |
| Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know |
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2024-12-26 12:01:18 |
Czytaj oryginał (ang.) |
| 8 Trading Lessons to Take From Our 2024 Stock Picks |
Subscribers to Chart of the Week received this commentary on Sunday, December 8. |
schaeffersresearch.com |
2024-12-24 11:59:55 |
Czytaj oryginał (ang.) |
| Gilead Sciences to Present at Upcoming Investor Conference |
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning at 11:15 a.m. Pacific Time The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days following the presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and. |
businesswire.com |
2024-12-20 18:05:00 |
Czytaj oryginał (ang.) |
| Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold? |
GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals. |
zacks.com |
2024-12-20 16:00:30 |
Czytaj oryginał (ang.) |
| Cash is Down, Valuations Are Up, but Stay Invested |
Bullish sentiment rules |
investorplace.com |
2024-12-19 21:04:36 |
Czytaj oryginał (ang.) |
| GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer |
Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell lung cancer indication. |
zacks.com |
2024-12-18 13:15:30 |
Czytaj oryginał (ang.) |
| 5 High Earnings Yield Value Picks to Buy for 2025 |
Unlock your portfolio value with these high earnings yield value stocks, PBI, GPOR, KINS, NATL and GILD. |
zacks.com |
2024-12-18 11:10:23 |
Czytaj oryginał (ang.) |
| Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure |
Gilead's stock has surged due to successful launches of Livdelzi for PBC and promising developments in lenacapavir for HIV prevention. Livdelzi's approval and strong market potential, combined with Gilead's robust HIV portfolio, position the company for significant revenue growth. Despite competition and debt, Gilead's financial health is solid, with substantial cash flow and manageable debt levels. |
seekingalpha.com |
2024-12-18 03:53:38 |
Czytaj oryginał (ang.) |
| 4 Big Drug Stocks That May Continue to Outperform in 2025 |
Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025. |
zacks.com |
2024-12-17 13:06:31 |
Czytaj oryginał (ang.) |
| U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. The Breakthrough Therapy Designation is based on results from the global Phase 2 TROPiCS-03 study ES-SCLC cohort. |
businesswire.com |
2024-12-17 10:30:00 |
Czytaj oryginał (ang.) |
| Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies |
FOSTER CITY, Calif. & LOS ANGELES--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. Terray's tNova platform combines high-throughput chemical experimentation and computational analysis with a generative AI-driven drug discovery engine. The company's iterative approach applies AI-empowered methods to an. |
businesswire.com |
2024-12-17 09:00:00 |
Czytaj oryginał (ang.) |
| GILD Obtains Positive CHMP Opinion for Liver Disease Drug |
The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid for the treatment of primary biliary cholangitis in adults. |
zacks.com |
2024-12-16 16:40:17 |
Czytaj oryginał (ang.) |
| Gilead (GILD) Upgraded to Buy: Here's Why |
Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-16 15:01:09 |
Czytaj oryginał (ang.) |
| Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. The final European Commission decision is a. |
businesswire.com |
2024-12-13 08:37:00 |
Czytaj oryginał (ang.) |
| Gilead appoints Sanofi official Dietmar Berger as next chief medical officer |
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave early next year. |
reuters.com |
2024-12-12 19:54:50 |
Czytaj oryginał (ang.) |
| Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead's senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therape. |
businesswire.com |
2024-12-12 19:30:00 |
Czytaj oryginał (ang.) |
| Is Gilead Sciences (GILD) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-12-12 12:41:33 |
Czytaj oryginał (ang.) |